Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Day One Biopharmaceuticals ( (DAWN) ) has issued an announcement.
Day One Biopharmaceuticals has completed a merger that changes control of the company and will result in its shares being delisted from Nasdaq and deregistered with the SEC. In connection with the closing, the company terminated its employee stock purchase plan and all equity compensation plans, and on April 20, 2026, it also ended its equity distribution agreement with Piper Sandler & Co. and JonesTrading Institutional Services.
On April 22, 2026, the company asked Nasdaq to halt trading in its shares ahead of the merger’s consummation and confirmed on April 23, 2026, that the deal had closed, after which all outstanding shares were converted into the right to receive merger consideration and former stockholders lost their rights except to that payment. The merger installed the purchaser’s directors and officers—led by David K. Lee and Danielle Button—as the new leadership team, removed the prior board and executives without any reported disputes, and replaced the company’s certificate of incorporation and bylaws with amended and restated governing documents aligned with its new private ownership structure.
The most recent analyst rating on (DAWN) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Spark’s Take on DAWN Stock
According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.
The score is held back primarily by ongoing losses and substantial negative free cash flow despite strong revenue growth and gross margins. Offsetting this, the latest earnings call reinforced strong commercial momentum and confident 2026 revenue guidance supported by a strong cash position, while technicals show an uptrend but with overbought conditions that add near-term risk.
To see Spark’s full report on DAWN stock, click here.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of oncology therapies. The company’s business centers on targeted cancer treatments, positioning it within the competitive market for innovative prescription medicines and clinical-stage cancer drug development.
Average Trading Volume: 3,971,727
Technical Sentiment Signal: Buy
Current Market Cap: $2.22B
For detailed information about DAWN stock, go to TipRanks’ Stock Analysis page.